TriNetX® will continue to support all existing Zetta Genomics customers utilizing the award-winning XetaBase® technology for research and patient care innovation

 -- TriNetX, the world's leading federated health data network, announced that it has acquired the key assets of Zetta Genomics, a Cambridge, UK-based healthcare technology company and current TriNetX partner. The acquisition expands TriNetX's genomics data management and analytics capabilities, supporting federated capture of multiomic data. This accelerates healthcare providers' ability to integrate phenotypic and multiomic data for improved care delivery and clinical research and enhances the ability of TriNetX's life science customers to perform large-data research in a cost-effective manner. 

Zetta's flagship platform, XetaBase, is a multiomic capture and analytics platform designed for population‑scale genomic analysis. XetaBase is currently in use by leading healthcare provider organizations, life sciences companies, and research institutes.

TriNetX and Zetta have worked closely together since 2024 as part of TriNetX's genomics data program. During this collaboration, the companies completed substantial technical feasibility work demonstrating secure, federated querying across genomic and phenotypic data to deliver high-integrity, analytically robust insights. This work establishes a strong foundation for further expansion.

"Through our partnership activities, led by our Chief Operating Officer Steve Kundrot and team, we have developed deep familiarity with Zetta's leadership, technological prowess, and fit-for-purpose approach and have been consistently impressed with Zetta's trusted healthcare provider relationships and robust analytics platform," said Jeff Margolis, Executive Chairman of TriNetX. "Welcoming Zetta's XetaBase platform into the TriNetX ecosystem represents an important milestone for our organization."

Mr. Margolis continued, "This acquisition reflects our commitment to advancing multiomic-enabled research and supporting healthcare providers with a practical, localized approach to scaling their data infrastructures."

Jeffrey Brown, PhD, TriNetX Chief Scientific Officer added, "Our purpose of driving better human health through data is clearly enhanced by adding the XetaBase technology, as we strongly believe the integration of different data types is essential to clinical and scientific progress." 

"I am proud of what the Zetta team has built and excited to see XetaBase become part of the TriNetX array of data, software, and intelligence capabilities," said Ignacio Medina Castello, Chief Executive Officer and Chief Technology Officer of Zetta Genomics. "From the beginning, our collaboration with TriNetX demonstrated that genomic and clinical data can be securely connected in a federated way at scale. Fully joining forces with TriNetX allows that work to move forward faster and to reach a broader global community of healthcare and research partners."